Revision of USP Chapter <1094> Capsules - Dissolution Testing And Related Quality Attributes Published for Comments

Recommendation
Thursday, 5 June 2025 9 .00 - 13.15 h
In the Pharmacopeial Forum, PF 48(4), a new version of USP Chapter <1094> Capsules—Dissolution Testing And Related Quality Attributes was published.
The chapter provides approaches for the development of dissolution test procedures for capsules. It also discusses quality attributes associated with capsules that may affect the outcome of dissolution testing.
Based on comments received on the version of the chapter official as of December 1, 2020, several revisions are being proposed. These include:
- References to USP chapter <1711> (Oral Dosage Forms—Performance Tests) and to FDA guidance on dissolution testing (Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances) were inserted
- The following four subchapters have been added:
- 4.1 Cleaning Considerations
- 5.6 In vitro in vivo Correlations
- 6.3 Brittleness
- 6.4 Overall Potential Capsule Defect Assessment. - Additional information, recommendations and examples have been added to various sections of the document.
In addition, minor editorial changes have been made.
Further information and a more detailed summary of the proposed revisions can be found in the document published on PF Online. The deadline for submitting comments is 30 September 2022.
Related GMP News
28.05.2025FDA Warning Letter for Chinese Manufacturer: Inadequate Testing and Stability Program Deficiencies
15.05.2025Update of USP Chapter <1099> on Content Uniformity in Large Samples
15.05.2025USP Education Webinar on <1058>
15.05.2025New ECA Guidance on Sampling and Sample Management